Immunic, Inc.
IMUX
$15.37
-$0.04-0.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.56M | 21.25M | 21.00M | 19.38M | 18.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 109.64M | 103.23M | 105.53M | 105.27M | 101.00M |
| Operating Income | -109.64M | -103.23M | -105.53M | -105.27M | -101.00M |
| Income Before Tax | -104.29M | -97.17M | -103.05M | -101.84M | -96.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.29 | -97.17 | -103.05 | -101.84 | -96.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.29M | -97.17M | -103.05M | -101.84M | -96.40M |
| EBIT | -109.64M | -103.23M | -105.53M | -105.27M | -101.00M |
| EBITDA | -109.48M | -103.06M | -105.37M | -105.10M | -100.85M |
| EPS Basic | -5.03 | -7.54 | -9.05 | -10.14 | -9.53 |
| Normalized Basic EPS | -3.09 | -4.66 | -5.66 | -6.34 | -5.96 |
| EPS Diluted | -5.03 | -7.54 | -9.05 | -10.14 | -9.53 |
| Normalized Diluted EPS | -3.09 | -4.66 | -5.66 | -6.34 | -5.96 |
| Average Basic Shares Outstanding | 30.19B | 58.82M | 49.46M | 40.20M | 40.46M |
| Average Diluted Shares Outstanding | 30.19B | 58.82M | 49.46M | 40.20M | 40.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |